Anemia News and Research RSS Feed - Anemia News and Research

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Agios begins AG-348 Phase 1 study for treatment of PK deficiency

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEM), today announced dose administration of AG-348 in a Phase 1 study in healthy volunteers. [More]

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder. [More]
Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis. [More]
New drug combination proves effective in treating patients with HCV genotype 1

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy. [More]
Doc receives grant for helping young adults to move from child-centered to adult-oriented health care system

Doc receives grant for helping young adults to move from child-centered to adult-oriented health care system

Oscar Taube, M.D., director of the Pediatric Outpatient department and the coordinator of Adolescent Medicine at the Herman & Walter Samuleson Children's Hospital at Sinai, has been awarded a grant from the American Academy of Pediatrics to provide adolescents, young adults and their family members with the tools to make a smooth transition from pediatric medical care to adult medical care. [More]
Scientists design new system for molecular blood group typing

Scientists design new system for molecular blood group typing

Scientists in France have designed a new system for molecular blood group typing that offers blood banks the possibility of extensive screening of blood donors at a relatively low cost. Their approach is described in the current issue of The Journal of Molecular Diagnostics. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection. [More]

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder. [More]
Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727. [More]
Physicians suspect that chemotherapy can accelerate aging process

Physicians suspect that chemotherapy can accelerate aging process

Physicians have long suspected that chemotherapy can accelerate the aging process in patients treated for cancer. Using a test developed at UNC Lineberger Comprehensive Cancer Center to determine molecular aging, UNC oncologists have directly measured the impact of anti-cancer chemotherapy drugs on biological aging. [More]

EORTC study does not support combination chemotherapy for soft tissue sarcoma

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor. [More]
Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

There have been a number of scientific publications recently that suggest that the radiation exposure from imaging tests can induce secondary cancers later in life. [More]
UCLA creates new program that helps adoptive parents, children navigate through international adoption process

UCLA creates new program that helps adoptive parents, children navigate through international adoption process

With thousands of internationally adopted children arriving in the United States each year, there is a growing demand for a specialized health-care support system that helps adoptive parents and children navigate through the international adoption process. [More]

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir AB today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia. [More]
Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

Patients with both HIV and hepatitis C have 80% higher rates of serious liver disease

A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV. [More]

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products. [More]
Study finds that same-day bilateral knee replacement surgery safe for select patients with RA

Study finds that same-day bilateral knee replacement surgery safe for select patients with RA

Same-day bilateral knee replacement surgery is safe for select patients with rheumatoid arthritis, researchers from Hospital for Special Surgery in New York have found. [More]
STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchymal stem cell therapy for the pulmonary fibrosis patient who visited Korea from Calgary, Canada. [More]
PCORI to award $7 million contract to Chicago coalition to establish clinical data research network

PCORI to award $7 million contract to Chicago coalition to establish clinical data research network

On December 17, 2013, the Patient-Centered Outcomes Research Institute (PCORI) announced its intention to award an 18-month, $7 million contract to a Chicago area coalition of 20 health and hospital organizations including Loyola University Health System. [More]